製品番号: HY-13551

Amsacrine

(別名: m-AMSA; acridinyl anisidide)

8 Cited Publications

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

Amsacrine (m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.91%
CAS 番号: 51264-14-3
分子式: C₂₁H₁₉N₃O₃S
分子量:393.46

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Amsacrine 構造式

CAS 番号: 51264-14-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (8)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Amsacrine (m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.

IC₅₀ & Target^[1]

Topoisomerase II

Topoisomerase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	4.31 μM Compound: m-AMSA	Cytotoxicity against human 2008 cells after 72 hrs by MTT assay Cytotoxicity against human 2008 cells after 72 hrs by MTT assay	[PMID: 19101158]
A2780	GI₅₀	0.027 μM Compound: m-AMSA	Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
A2780	IC₅₀	0.1 μM Compound: m-AMSA	Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells. Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.	[PMID: 7658436]
A2780	IC₅₀	0.35 μM Compound: m-AMSA	Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line	[PMID: 9871638]
A-431	IC₅₀	0.17 μM Compound: 1, m-AMSA	Growth inhibition in human A431 cells after 72 hrs by trypan blue assay Growth inhibition in human A431 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
A-431	IC₅₀	5.89 μM Compound: m-AMSA	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	0.03 μM Compound: 1	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	IC₅₀	22.2 μM Compound: m-Amsa	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
A549	IC₅₀	3.52 μM Compound: m-AMSA	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19101158]
A549	IC₅₀	5.96 μM Compound: 2; m-AMSA	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.03 μM Compound: m-AMSA	Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay Antiproliferative against human CCRF-CEM cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
CCRF-CEM	IC₅₀	0.139 μM Compound: m-AMSA	The compound was tested for the cytotoxicity against human leukemic CCRF-CEM cell lines The compound was tested for the cytotoxicity against human leukemic CCRF-CEM cell lines	[PMID: 7650675]
CCRF-CEM	IC₅₀	0.18 μM Compound: 2; m-AMSA	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	130 nM Compound: amsacrine	Cytotoxicity against human CCRF-CEM cells after 72 hrs Cytotoxicity against human CCRF-CEM cells after 72 hrs	[PMID: 18329887]
CCRF-CEM	IC₅₀	130 μM Compound: Amsacrine	Cytotoxicity in human leukemic CCRF-CEM cells. Cytotoxicity in human leukemic CCRF-CEM cells.	[PMID: 14667232]
CEM-VLB	IC₅₀	0.52 μM Compound: m-AMSA	The compound was tested for the cytotoxicity against human leukemic CEM/VBL cell lines The compound was tested for the cytotoxicity against human leukemic CEM/VBL cell lines	[PMID: 7650675]
CEM-VM1	IC₅₀	1.91 μM Compound: m-AMSA	The compound was tested for the cytotoxicity against human leukemic CEM/VM-1 cell lines The compound was tested for the cytotoxicity against human leukemic CEM/VM-1 cell lines	[PMID: 7650675]
CHO-AA8	IC₅₀	0.6 nM Compound: Amsacrine	Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours) Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)	[PMID: 2909741]
COLO 205	IC₅₀	1.1 μM Compound: Amsacrine	Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 22546208]
DC3F	IC₅₀	0.004 μM Compound: m-AMSA	The compound was tested for the cytotoxicity DC-3F cell lines The compound was tested for the cytotoxicity DC-3F cell lines	[PMID: 7650675]
DC3F/AD-II	IC₅₀	0.047 μM Compound: m-AMSA	The compound was tested for the cytotoxicity against human leukemic DC-3F/ADII cell lines, activity is expressed as IC50 values. The compound was tested for the cytotoxicity against human leukemic DC-3F/ADII cell lines, activity is expressed as IC50 values.	[PMID: 7650675]
DLD-1	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by Hoechst test Cytotoxicity against human DLD1 cells by Hoechst test	[PMID: 18656367]
DLD-1	IC₅₀	0.57 μM Compound: amsacrine	Cytotoxicity against human DLD1 cells by resazurin reduction test Cytotoxicity against human DLD1 cells by resazurin reduction test	[PMID: 18656367]
DU-145	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22546208]
F460pv8/eto	IC₅₀	0.04 μM Compound: 1	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
Fibroblast	IC₅₀	2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by Hoechst test Cytotoxicity against human fibroblast cells by Hoechst test	[PMID: 18656367]
Fibroblast	IC₅₀	4.2 μM Compound: amsacrine	Cytotoxicity against human fibroblast cells by resazurin reduction test Cytotoxicity against human fibroblast cells by resazurin reduction test	[PMID: 18656367]
HCC1937	IC₅₀	7.85 μM Compound: m-AMSA	Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC1937 cells harboring BRCA1 mutant after 72 hrs by MTT assay	[PMID: 28763648]
HCT-116	IC₅₀	<1 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29954683]
HCT-116	IC₅₀	0.7 μM Compound: m-AMSA	Cytotoxicity against human HCT116 cells by XTT assay Cytotoxicity against human HCT116 cells by XTT assay	[PMID: 17368022]
HCT-116	IC₅₀	0.93 μM Compound: 2; m-AMSA	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	3.89 μM Compound: m-AMSA	Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells expressing topoisomerase-1 after 72 hrs by MTT assay	[PMID: 28763648]
HCT-116	IC₅₀	6.3 μM Compound: m-AMSA	Cytotoxicity against HCT116 cells. Cytotoxicity against HCT116 cells.	[PMID: 7473578]
HCT-116	IC₅₀	6.3 μM Compound: m-AMSA	Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116 Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116	[PMID: 7525959]
HCT-15	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22546208]
HCT-8	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22546208]
HCT-8	IC₅₀	120 nM Compound: 1	In vitro for the inhibition of human colon tumor (HCT-8) cells. In vitro for the inhibition of human colon tumor (HCT-8) cells.	[PMID: 3560159]
HCT-8	IC₅₀	120 nM Compound: 1	In vitro for cytotoxicity against human colon tumor cells (HCT-8) in culture In vitro for cytotoxicity against human colon tumor cells (HCT-8) in culture	[PMID: 3755758]
HEK293	IC₅₀	5 μM Compound: amsacrine	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	[PMID: 18788725]
HeLa	EC₅₀	0.72 μM Compound: 5 (m-AMSA)	Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay Tested for inhibition of topoisomerase II isolated from HeLa cells by DNA-cleavage assay	[PMID: 8410993]
HeLa	EC₅₀	0.72 μM Compound: mAMSA	Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method Compound was tested for topoisomerase II inhibition in purified HeLa cells by SDS/K+ precipitation method	10.1016/0960-894X(95)00044-T
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II. Inhibitory activity in a cell-free assay of DNA cleavage mediated by purified HeLa cell topoisomerase II.	10.1016/0960-894X(95)00043-S
HeLa	EC₅₀	0.72 μM Compound: m-AMSA	Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method Tested for inhibitory activity against Topoisomerase II isolated from HeLa cells by using SDS-K+ precipitation method	10.1016/S0960-894X(00)80048-7
HeLa	EC₅₀	0.72 μM Compound: mAMSA	In vitro inhibitior of human DNA topoisomerase II from HeLa cells. In vitro inhibitior of human DNA topoisomerase II from HeLa cells.	[PMID: 9733489]
HeLa	EC₅₀	0.72 μM Compound: mAMSA	Inhibitory activity against HeLa cell Topoisomerase II Inhibitory activity against HeLa cell Topoisomerase II	10.1016/0960-894X(95)00160-U
HeLa	EC₅₀	0.72 μM Compound: mAMSA	Inhibition of topoisomerase II purified from HeLa cells Inhibition of topoisomerase II purified from HeLa cells	10.1016/0960-894X(96)00230-2
HeLa	GI₅₀	0.031 μM Compound: m-AMSA	Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
HeLa	IC₅₀	0.012 μM Compound: 1, m-AMSA	Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay Growth inhibition in human HeLa cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HeLa	IC₅₀	0.012 μM Compound: m-amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue test	[PMID: 18077173]
HeLa	IC₅₀	0.34 μM Compound: 2; m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	IC₅₀	19.19 μM Compound: m-AMSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28511910]
HeLa	IC₅₀	9.5 μM Compound: Amsacrine	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18035542]
HeLa	IC₅₀	9.5 μM Compound: m-AMSA	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19364657]
HepG2	IC₅₀	5.21 μM Compound: m-AMSA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28511910]
HL-60	IC₅₀	0.0051 μM Compound: m-amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test Antiproliferative activity against human HL60 cells after 72 hrs by trypan blue test	[PMID: 18077173]
HL-60	IC₅₀	0.006 μM Compound: 1, m-AMSA	Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay Growth inhibition in human HL60 cells after 72 hrs by trypan blue assay	[PMID: 21216603]
HL-60	IC₅₀	0.021 μM Compound: m-AMSA	In vitro cytotoxicity against human leukemic HL-60 cell line. In vitro cytotoxicity against human leukemic HL-60 cell line.	[PMID: 7650675]
HL-60	IC₅₀	0.08 μM Compound: Amsacrine	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 22546208]
HL-60	IC₅₀	0.4 μM Compound: m-AMSA	Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line Cell cytotoxicity was determined against human promyelocytic leukemia (HL60) cell line	[PMID: 9871638]
HL-60	IC₅₀	1.15 μM Compound: m-AMSA	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19101158]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay Antiproliferative activity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-1080	GI₅₀	1.6 μM Compound: m-Amsa	Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT1080 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 18403058]
HT-29	GI₅₀	16.8 μM Compound: m-Amsa	Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
HT-29	IC₅₀	559 nM Compound: m-AMSA	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
J774	IC₅₀	900.6 nM Compound: m-AMSA	Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells	10.1016/0960-894X(95)00300-I
J774.2	IC₅₀	1353.9 nM Compound: m-AMSA	Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells	10.1016/0960-894X(95)00300-I
J774.2	IC₅₀	1485.2 nM Compound: m-AMSA	Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells	10.1016/0960-894X(95)00300-I
Jurkat	IC₅₀	<1 μM Compound: 3	Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure	[PMID: 8182707]
Jurkat	IC₅₀	0.02 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by Hoechst test Cytotoxicity against human Jurkat cells by Hoechst test	[PMID: 18656367]
Jurkat	IC₅₀	0.08 μM Compound: amsacrine	Cytotoxicity against human Jurkat cells by resazurin reduction test Cytotoxicity against human Jurkat cells by resazurin reduction test	[PMID: 18656367]
Jurkat	IC₅₀	0.2 μM Compound: 3	Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures Concentration required to reduce the growth of human Jurkat cells to 50% of control cultures	[PMID: 9258370]
Jurkat	IC₅₀	37 nM Compound: amsacrine	Concentration required to inhibit 50% growth of human Jurkat cells Concentration required to inhibit 50% growth of human Jurkat cells	[PMID: 10395479]
Jurkat	IC₅₀	37 nM Compound: Amsacrine	Inhibitory activity against Jurkat human leukemia cells Inhibitory activity against Jurkat human leukemia cells	[PMID: 11384245]
Jurkat	IC₅₀	37 nM Compound: amsacrine	Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures Inhibitory concentration required to reduce human Jurkat leukemia (JLC sensitive, wild type) cell number to 50% of control cultures	[PMID: 9191970]
K562	IC₅₀	0.023 μM Compound: amsacrine (m-AMSA)	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
K562	IC₅₀	0.71 μM Compound: m-AMSA	Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay Antiproliferative against human K562 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
K562	IC₅₀	0.88 μM Compound: m-AMSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28511910]
K562	IC₅₀	13.8 μM Compound: m-Amsa	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
K562	IC₅₀	19.9 μM Compound: Amsacrine	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 18035542]
K562	IC₅₀	19.9 μM Compound: m-AMSA	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19364657]
KB	IC₅₀	<0.3 μg/mL Compound: m-AMSA	Inhibition of KB cell growth in vitro Inhibition of KB cell growth in vitro	[PMID: 2542558]
L1210	IC₅₀	0.05 μM Compound: m-AMSA	Inhibitory concentration against L1210 leukemic cell proliferation over 24 hr Inhibitory concentration against L1210 leukemic cell proliferation over 24 hr	[PMID: 7658436]
L1210	IC₅₀	33 nM Compound: 1	In vitro inhibitory activity against Murine leukemia (L1210) In vitro inhibitory activity against Murine leukemia (L1210)	[PMID: 3560159]
L1210	IC₅₀	33 nM Compound: 1	In vitro for cytotoxicity against murine leukemia cells (L1210) In vitro for cytotoxicity against murine leukemia cells (L1210)	[PMID: 3755758]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Antiproliferative activity against human M21 cells after 48 hrs by SRB assay Antiproliferative activity against human M21 cells after 48 hrs by SRB assay	[PMID: 18403058]
M21	GI₅₀	49.6 μM Compound: m-Amsa	Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human M21 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
M4Beu cell line	IC₅₀	0.4 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by Hoechst test Cytotoxicity against human M4Beu cells by Hoechst test	[PMID: 18656367]
M4Beu cell line	IC₅₀	0.74 μM Compound: amsacrine	Cytotoxicity against human M4Beu cells by resazurin reduction test Cytotoxicity against human M4Beu cells by resazurin reduction test	[PMID: 18656367]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 18403058]
MCF7	GI₅₀	5.6 μM Compound: m-Amsa	Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytocidal activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22503207]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53) Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)	[PMID: 10780913]
MCF7	IC₅₀	0.075 μM Compound: 1	Inhibitory activity against MCF7wt cell line using MTT assay Inhibitory activity against MCF7wt cell line using MTT assay	[PMID: 10780913]
MCF7	IC₅₀	0.91 μM Compound: m-Amsa	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 17368022]
MCF7	IC₅₀	21.7 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells by XTT assay Cytotoxicity against human MCF7 cells by XTT assay	[PMID: 18093835]
MCF7	IC₅₀	26.76 μM Compound: 2; m-AMSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27060757]
MCF7	IC₅₀	5.13 μM Compound: m-AMSA	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19101158]
MCF7	IC₅₀	8.7 μM Compound: m-AMSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28763648]
MDA-MB-231	IC₅₀	0.14 μM Compound: 1	Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53) Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)	[PMID: 10780913]
MDA-MB-231	IC₅₀	10.05 μM Compound: m-AMSA	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29954683]
MDA-MB-468	IC₅₀	0.49 μM Compound: 1	Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53) Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)	[PMID: 10780913]
MDA-MB-468	IC₅₀	8.5 μM Compound: m-AMSA	Cytotoxicity against human MDA-MB468 cells by XTT assay Cytotoxicity against human MDA-MB468 cells by XTT assay	[PMID: 17368022]
MRC5	IC₅₀	15.4 μM Compound: m-Amsa	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33479643]
MSTO-211H	GI₅₀	0.019 μM Compound: m-AMSA	Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
NCI/ADR-RES	IC₅₀	1.165 μM Compound: 1	Inhibitory activity against MCF-7/adr cell line using MTT assay Inhibitory activity against MCF-7/adr cell line using MTT assay	[PMID: 10780913]
NCI-H226	IC₅₀	1.01 μM Compound: 1	Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H322M	IC₅₀	0.21 μM Compound: 1	Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H358	IC₅₀	0.15 μM Compound: 1	Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay Inhibitory activity against NCI-H460 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53) Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.2 μM Compound: 1	Inhibitory activity against H460pv8 cell line using MTT assay Inhibitory activity against H460pv8 cell line using MTT assay	[PMID: 10780913]
NCI-H647	IC₅₀	0.07 μM Compound: 1	Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)	[PMID: 10780913]
OVCAR-8	IC₅₀	1.4 μM Compound: Amsacrine	Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 22546208]
P388	IC₅₀	0.012 μM Compound: 3 (Amsacrine)	In vitro cell growth inhibitory activity against wild type P388 murine leukemia cell line (P388/W) In vitro cell growth inhibitory activity against wild type P388 murine leukemia cell line (P388/W)	[PMID: 2153829]
P388	IC₅₀	0.15 μM Compound: mAMSA	In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells. In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.	[PMID: 9733489]
P388	IC₅₀	0.15 μM Compound: mAMSA	In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound	10.1016/0960-894X(96)00230-2
P388	IC₅₀	0.15 μM Compound: mAMSA	In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound In vitro cytotoxicity was evaluated following 1 hour transient exposure of P388 mouse leukemia cells to the compound	10.1016/0960-894X(95)00044-T
P388	IC₅₀	0.15 μM Compound: mAMSA	In vitro cytotoxicity against P388 mouse leukemia cells In vitro cytotoxicity against P388 mouse leukemia cells	10.1016/0960-894X(95)00160-U
P388	IC₅₀	0.89 μM Compound: 3 (Amsacrine)	In vitro cell growth inhibitory activity was determined against amsacrine-resistant P388 cell line (P388/A). In vitro cell growth inhibitory activity was determined against amsacrine-resistant P388 cell line (P388/A).	[PMID: 2153829]
P388	IC₅₀	20 nM Compound: amsacrine	Inhibitory activity against Murine p38 leukemia Inhibitory activity against Murine p38 leukemia	[PMID: 10395479]
P388	IC₅₀	20 nM Compound: Amsacrine	Inhibitory activity against P388 murine leukemia cells Inhibitory activity against P388 murine leukemia cells	[PMID: 11384245]
P388	IC₅₀	20 nM Compound: amsacrine	Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures Inhibitory concentration required to reduce murine p388 leukemia cell number to 50% of control cultures	[PMID: 9191970]
P388	IC₅₀	229 nM Compound: m-AMSA	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	21.7 μM Compound: Amsacrine	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 22546208]
PC-3	IC₅₀	3.3 μM Compound: Amsacrine	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22546208]
RAW264.7	CC₅₀	95.5 μM Compound: m-Amsa	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
SF-295	IC₅₀	0.5 μM Compound: Amsacrine	Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay	[PMID: 22546208]
SK-BR-3	IC₅₀	0.06 μM Compound: 1	Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53) Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)	[PMID: 10780913]
SW480	IC₅₀	27.7 μM Compound: Amsacrine	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	[PMID: 18035542]
SW480	IC₅₀	27.7 μM Compound: m-AMSA	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19364657]
SW-620	IC₅₀	0.3 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 22546208]
SW-620	IC₅₀	16.7 μM Compound: Amsacrine	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 18035542]
SW-620	IC₅₀	16.7 μM Compound: m-AMSA	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 19364657]
T47D	IC₅₀	0.22 μM Compound: 1	Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53) Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)	[PMID: 10780913]
T47D	IC₅₀	0.94 μM Compound: m-Amsa	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31421632]
U-937	IC₅₀	0.08 μM Compound: m-AMSA	Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 31635931]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28511910]
U-937	IC₅₀	0.61 μM Compound: m-AMSA	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29954683]
V79	IC₅₀	5.8 μM Compound: Amsacrine	Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay Cytotoxicity against chinese hamster V79 cells after 72 hrs by MTT assay	[PMID: 22546208]
XRS6	IC₅₀	0.24 μM Compound: m-AMSA	Cytotoxicity against CHO cell line xrs6 Cytotoxicity against CHO cell line xrs6	[PMID: 7473578]
ZR-75-1	IC₅₀	0.18 μM Compound: 1	Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53) Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)	[PMID: 10780913]

体外実験

Amsacrine (m-AMSA) blocks HERG currents in HEK 293 cells and Xenopus oocytes in a concentration-dependent manner, with IC₅₀ values of 209.4 nm and 2.0 μM, respectively. Amsacrine (m-AMSA) causes a negative shift in the voltage dependence of both activation (?7.6 mV) and inactivation (?7.6 mV). HERG current block by amsacrine is not frequency dependent^[1]. In vitro studies of normal human lymphocytes with various concentrations of Amsacrine (m-AMSA), show both increased levels of chromosomal aberrations, ranging from 8% to 100%, and increase SCEs, ranging from 1.5 times the normal at the lowest concentration studied (0.005 μg/mL) to 12 times the normal (0.25 μg/mL)^[3]. Amsacrine (m-AMSA)-induced apoptosis of U937 cells is characterized by caspase-9 and caspase-3 activation, increased intracellular Ca²⁺ concentration, mitochondrial depolarization, and MCL1 down-regulation. Amsacrine (m-AMSA) induces MCL1 down-regulation by decreasing its stability. Further, amsacrine-treated U937 cells show AKT degradation and Ca²⁺-mediated ERK inactivation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

In animals treated with different doses of amsacrine (0.5-12 mg/kg), the frequencies of micronucleated polychromatic erythrocytes increase significantly after treatment with 9 and 12 mg/kg. Furthermore, the present study demonstrates for the first time that Amsacrine (m-AMSA) has high incidences of clastogenicity and low incidences of aneugenicity whereas nocodazole has high incidences of aneugenicity and low incidences of clastogenicity during mitotic phases in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 51264-14-3
性状 Solid
分子量 393.46
分子式 C₂₁H₁₉N₃O₃S
Color Orange to red
SMILES

CS(=O)(NC1=CC=C(NC2=C(C=CC=C3)C3=NC4=CC=CC=C42)C(OC)=C1)=O
別名

m-AMSA; acridinyl anisidide
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All

Sort by:

Journal Impact Factor

Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
J Adv Res

Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages. [Abstract]

2024 Apr:58:117-128. PMID: 37290606
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Nucleic Acid Ther

Mammalian Target of Rapamycin Inhibition Enhances Delivery and Activity of Antisense Oligonucleotides in Uveal Melanoma Cells. [Abstract]

2023 Aug;33(4):248-264. PMID: 37389884
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
University of Colorado Denver

2024.
bioRxiv

September 29, 2021.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (254.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5416 mL

12.7078 mL

25.4155 mL

5 mM

0.5083 mL

2.5416 mL

5.0831 mL

10 mM

0.2542 mL

1.2708 mL

2.5416 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Animal Administration^[2]

Amsacrine (m-AMSA) is investigated in three separated experiments. In the first experiment, animals are treated by intraperitoneal injection with 0.5, 1.5 and 4.5 mg/kg of amsacrine and bone marrow is sampled 24 h after treatment. Preliminary negative MN results at this sampling time lead to the use of 30 h sampling time for amsacrine. Thus, in the second experiment, mice are treated with 0.5, 1.5 and 4.5 mg/kg of Amsacrine (m-AMSA) and bone marrow is sampled 30 h after treatment. The doses and sampling times for amsacrine are chosen by reference to earlier studies and the selected doses are within the dose range used for human chemotherapy. The results again show that the micronuclei frequency in the bone marrow of mice is not affected by treatment with any of the selected doses of the test agent, at 30 h sampling time, thus, in the third experiment, mice are treated with 6, 9 and 12 mg/kg of amsacrine and bone marrow is sampled 24 and 30 h after treatment.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94. [Content Brief]

[2]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33. [Content Brief]

[3]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97. [Content Brief]

[4]. Lee YC, et al. Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1. Apoptosis. 2016 Oct 19 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5416 mL	12.7078 mL	25.4155 mL	63.5389 mL
	5 mM	0.5083 mL	2.5416 mL	5.0831 mL	12.7078 mL
	10 mM	0.2542 mL	1.2708 mL	2.5416 mL	6.3539 mL
	15 mM	0.1694 mL	0.8472 mL	1.6944 mL	4.2359 mL
	20 mM	0.1271 mL	0.6354 mL	1.2708 mL	3.1769 mL
	25 mM	0.1017 mL	0.5083 mL	1.0166 mL	2.5416 mL
	30 mM	0.0847 mL	0.4236 mL	0.8472 mL	2.1180 mL
	40 mM	0.0635 mL	0.3177 mL	0.6354 mL	1.5885 mL
	50 mM	0.0508 mL	0.2542 mL	0.5083 mL	1.2708 mL
	60 mM	0.0424 mL	0.2118 mL	0.4236 mL	1.0590 mL
	80 mM	0.0318 mL	0.1588 mL	0.3177 mL	0.7942 mL
	100 mM	0.0254 mL	0.1271 mL	0.2542 mL	0.6354 mL

Keywords

Amsacrine

8 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Amsacrine

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Amsacrine

Topoisomerase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amsacrine

Cell Cycle/DNA Damage Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 Amsacrine

Topoisomerase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (8)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Amsacrine 関連分類

HY-13551 関連分類